Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced today its scheduled presentation of the company's programs and outlook at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015, at 2:20 p.m. ET, in New York. A copy of the presentation will be available in the Investor Center of the company's website at (Original Source)

Shares of Conatus closed yesterday at $6.07 . CNAT has a 1-year high of $11.74 and a 1-year low of $5.06. The stock's 50-day moving average is $6.27 and it's 200-day moving average is $6.74.

On the ratings front, Conatus has been the subject of a number of recent research reports. In a report issued on March 27, Piper Jaffray analyst Charles Duncan reiterated a Buy rating on CNAT, with a price target of $9, which implies an upside of 48.3% from current levels. Separately, on March 26, MLV & Co.'s Vernon Bernardino reiterated a Buy rating on the stock and has a price target of $16.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Charles Duncan and Vernon Bernardino have a total average return of 10.6% and -11.4% respectively. Duncan has a success rate of 53.3% and is ranked #787 out of 3568 analysts, while Bernardino has a success rate of 34.7% and is ranked #3502.

The street is mostly Bullish on CNAT stock. Out of 4 analysts who cover the stock, 4 suggest a Buy rating . The 12-month average price target assigned to the stock is $12.75, which represents a potential upside of 110.0% from where the stock is currently trading.

Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.